Public JSC Pharmstandard has completed its restructuring through the spin-off of PJSC OTCPharm as a standalone business, Pharmstandard informed.
The date of State Registration of OTCPharm is December 23, 2013.
The distribution ratio for OTC shares is 4 to 1, i.e. 4 OTCPharm common shares per each Pharmstandard common share.
OTC shares are to be distributed among all the shareholders at the date of OTCPharm registration.
Trading activities on MOEX will be resumed as per MOEX listing rules.
Public JSC Pharmstandard (tax number: 0274110679) is a domestic pharmaceutical company established in 2003. Pharmstandard produces more than 250 medicine names including Arbidol«, Complivit«, Pentalgin«, Flucostat«, Phosphogliv«, Amixin«, Afobazole«, Rastan« and Biosulin«.
Pharmstandard Group's production activities are located at four medicine production facilities (OJSC Pharmstandard-Leksredstva in Kursk, OJSC Pharmstandard-UfaVITA in Ufa), OJSC Pharmstandard-Tomskkhimfarm in Tomsk), PJSC Pharmstandard-Biolek in Kharkov, Ukraine), Tyumen Plant of Medical Equipment and Tools (OJSC TZMOI, Tyumen) as well as Pharmstandard LLC purchasing and delivering raw materials to Pharmstandard Group's production facilities for further production of pharmaceuticals.
The company's shareholding structure is as follows: Ogment Investmenns Limited (54.3185%, both common shares and GDRs), OJSC Pharmstandard-Leksredstva (18.7392%, both common shares and GDRs).
RAS net profit of PJSC Pharmstandard for January-September 2013 grew by 21% to RUB 4.676 billion from RUB 3.865 billion for the same period last year. Revenue increased by 8.4% to RUB 13.233 billion from RUB 12.209 billion, sales profit by 4.6% to RUB 5.534 billion from RUB 5.29 billion, pre-tax profit by 20.3% to RUB 5.831 billion from RUB 4.847 billion.